Back

Apolipoprotein E4 as a genetic biomarker of mortality in patients with dilated cardiomyopathy

28 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Risk stratification in idiopathic dilated cardiomyopathy Idiopathic Dilated Cardiomyopathy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Rodica Diaconu

CardioEcho Clinic, Craiova (Romania)

7 More presentations in this session

Presentation thumbnail
Diagnostic and prognostic value of exercise-induced ventricular arrhythmias in genetic dilated cardiomyopathy
Miss N. Kalf (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Integrated cardiac magnetic resonance and plasma proteomics for phenotyping and risk stratification in idiopathic dilated cardiomyopathy
Doctor A. Wu (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
The “negative” side of cardiomyopathy: phenotype and arrhythmic risk in gene-elusive patients
Doctor M. Martini (Padova, IT)
Abstract Slides Video
Presentation thumbnail
Exercise stress test arrhythmic patterns by genotype in non-desmosomal arrhythmogenic cardiomyopathy
Doctor A. Sularz (Rochester, US)
Abstract Slides Video
Presentation thumbnail
The sodium–glucose co-transporter 2 inhibitor canagliflozin, attenuates cardiac fibrosis and function in inflammatory dilated cardiomyopathy
Miss J. Wang (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Risk stratification in idiopathic dilated cardiomyopathy

The Event

Event poster

ESC Congress 2026

28 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Cardiac function and the effect of heart failure treatment in patients with genotype-positive dilated cardiomyopathy
28 August 2026
thumbnail
Congress Presentation
CSTB, FABP4, IBP-1 and ST2 are strong predictors of mortality after transcatheter edge-to-edge mitral valve repair
30 August 2024
thumbnail
Congress Presentation
Cardiovascular prognosis in stable patients with amyloidosis: a novel and simple risk score.
31 August 2025
thumbnail
Congress Presentation
The Apolipoprotein A2/Apolipoprotein C3 ratio predicts future cardiovascular events after percutaneous coronary intervention in patients receiving LDL-cholesterol-lowering therapy
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources